CISPLATIN, CARBOPLATIN, KEYTRUDA 25 mg/mL concentrate for solution for infusion, CISPLATIN, FLUOROURACIL clinical trials

An Open-label, Dose Escalation, Phase 1/2 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of TAK-676 as a Single Agent and in Combination With Pembrolizumab in Adult Patients With Advanced or Metastatic Solid Tumors

This study is testing a new drug, TAK-676, for adults with advanced solid cancers. It aims to see if TAK-676 is safe, how well it's tolerated, and how it works, both alone and with another cancer drug called Pembrolizumab (Keytruda).